Drugs - Daklinza, Epclusa, Harvoni, Mavyret, Olysio, Sovaldi, Technivie, Viekira Pak, Viekira XR, Vosevi, Zepatier
November 2017
Therapeutic area - Hepatitis C Direct Acting Antivirals
At the time of treatment initiation, patient must have evidence of Minnesota Health Care Programs (MHCP) insurance coverage for the duration of treatment.
Genotype 1 Treatment-Naive Patients
Preferred | Nonpreferred |
Mavyret |
Zepatier
|
Genotype 1 Treatment-Experienced Patients
Preferred | Nonpreferred |
Mavyret
Vosevi |
None |
Genotype 2 Treatment-Naïve Patients
Preferred | Nonpreferred |
Mavyret | Epclusa
Sovaldi |
Genotype 2 Treatment-Experienced Patients
Preferred | Nonpreferred |
Mavyret
Vosevi |
None |
Genotype 3 Treatment-Naïve Patients
Preferred | Nonpreferred |
Mavyret | Epclusa
Sovaldi Daklinza |
Genotype 3 Treatment-Experienced Patients
Preferred | Nonpreferred |
Mavyret
Vosevi |
None |
Genotype 4 Treatment-Naïve Patients
Preferred | Nonpreferred |
Mavyret | Technivie
Zepatier Harvoni Epclusa Sovaldi |
Genotype 4 Treatment-Experienced Patients
Preferred | Nonpreferred |
Mavyret
Vosevi |
None |
Genotype 5 or 6 Treatment-Naïve Patients
Preferred | Nonpreferred |
Mavyret | Harvoni
Epclusa |
Genotype 5 or 6 Treatment-Experienced Patients
Preferred | Nonpreferred |
Mavyret
Vosevi |
None |
Treatment-Naïve Patients
Preferred | Nonpreferred |
Mavyret | Zepatier
Viekira Pak/Viekira XR Harvoni Epclusa Sovaldi Olysio Daklinza |
Treatment-Experienced Patients
Preferred | Nonpreferred |
Mavyret
Vosevi |
None |
Criteria 1: Regimen is prescribed by (or had a documented consult with) a gastroenterologist, hepatologist, infectious disease specialist, or a practitioner specializing in the treatment of hepatitis. Notes of consultation with specialist must be attached to authorization request AND
Criteria 2: Both the treating clinician and the patient are confident that the patient can effectively start and successfully adhere to treatment. The treating clinician must attest that the patient has been evaluated for “readiness” for treatment, including identification of potential impediments to effective treatment (e.g., difficulties with compliance, missing appointments, adequate social support, and adequate control of mental health conditions, alcohol use disorder, and IV drug use). Potential impediments to successful treatment must be addressed in treatment notes prior to initiating treatment and submitted with authorization request. Specifically:
Criteria 3: The treating clinician must provide documentation to attest the patient is screened for evidence of current or prior hepatitis B virus (HBV) infection before starting treatment with direct acting antivirals. The treating clinician must also have a monitoring plan in place for HBV flare-ups or reactivation during treatment and post-treatment follow up AND
Criteria 4: Clinical documentation of patient’s liver cirrhosis status (e.g., no cirrhosis, compensated cirrhosis, etc.) that corresponds to the requested therapy duration AND
Criteria 5: Pretreatment detectable HCV RNA viral load value, measured within 1 year of treatment start date, are provided at time of request AND
Criteria 6: Provider attests to submits SVR12 results to the Department via fax at 651-431-7424 or upon request AND
Criteria 7: Patient is 18 years of age or older with a diagnosis of hepatitis C, genotype 1.
For patients under the age of 18 requesting Harvoni:
Patient has met Criteria 1 through 6 of the Preferred Drug Criteria AND
Patient has a diagnosis of hepatitis C, genotype 1 AND
Patient meets either of the following:
For patients over the age of 18:
Patient has met Criteria 1 through 7 of the Preferred Drug Criteria AND
Patient meets the drug specific criteria in Table 2, Tier Approach to Nonpreferred Drugs for Treatment-Naïve, Genotype 1 AND
Patient has HCV infection with at least ONE of the four conditions listed below:
Tier | Nonpreferred Drug | PA Criteria Genotype 1, age > 18 |
1 | Zepatier | Must meet all PA criteria for nonpreferred drug above and patient has renal impairment. If applicable, prescriber provides rationale that potential drug interaction(s) between the patient’s current medication regimen and the preferred or other nonpreferred agents cannot be mitigated. |
2 | Viekira Pak/Viekira XR | Must meet all PA criteria for nonpreferred drug above, have a contraindication to Zepatier. Patient also must have creatinine clearance (CrCL) > 30 mL/min OR not currently on hemodialysis. |
3 | Harvoni | Must meet all PA criteria for nonpreferred drug above and have a contraindication to Zepatier and Viekira Pak/Viekira XR. Patient also must have creatinine clearance (CrCL) > 30 mL/min OR not currently on hemodialysis. |
4 | Epclusa | Must meet all PA criteria for nonpreferred drug above and have a contraindication to Zepatier and Viekira Pak/Viekira XR and supply clinical rationale as to why Harvoni cannot be used. Patient also must have creatinine clearance (CrCL) > 30 mL/min OR not currently on hemodialysis. |
5 | Sovaldi | Must meet all PA criteria for nonpreferred drug above and have a contraindication to Zepatier and Viekira Pak/Viekira XR and supply clinical rationale as to why Harvoni and Epclusa cannot be used. Patient also must have creatinine clearance (CrCL) > 30 mL/min OR not currently on hemodialysis. |
6 | Olysio | Must meet all PA criteria for nonpreferred drug above and have a contraindication to Zepatier and Viekira Pak/Viekira XR and supply clinical rationale as to why Harvoni and Epclusa cannot be used. Patient also must have creatinine clearance (CrCL) > 30 mL/min OR not currently on hemodialysis. Olysio must be used in combination with Sovaldi or Peg-IFN-alfa and ribavirin. |
7 | Daklinza | Must meet all PA criteria for nonpreferred drug above and have a contraindication to Zepatier and Viekira Pak/Viekira XR and supply clinical rationale as to why Harvoni and Epclusa and Olysio cannot be used. Patient also must have creatinine clearance (CrCL) > 30 mL/min OR not currently on hemodialysis. Daklinza must be used in combination with Sovaldi. |
Criteria 1: Regimen is prescribed by (or had a documented consult with) a gastroenterologist, hepatologist, infectious disease specialist, or a practitioner specializing in the treatment of hepatitis. Notes of consultation with specialist must be attached to authorization request AND
Criteria 2: Both the treating clinician and the patient are confident that the patient can effectively start and successfully adhere to treatment. The treating clinician must attest that the patient has been evaluated for “readiness” for treatment, including identification of potential impediments to effective treatment (e.g., difficulties with compliance, missing appointments, adequate social support, and adequate control of mental health conditions, alcohol use disorder, and IV drug use). Potential impediments to successful treatment must be addressed in treatment notes prior to initiating treatment and submitted with authorization request. Specifically:
Criteria 3: The treating clinician must provide documentation to attest that the patient is screened for evidence of current or prior hepatitis B virus (HBV) infection before starting treatment with direct acting antivirals AND the provider has a monitoring plan for HBV flare-ups or reactivation during treatment and post-treatment follow-up AND
Criteria 4: Clinical documentation of patient’s liver cirrhosis status (e.g., no cirrhosis, compensated cirrhosis, etc.) that corresponds to the requested therapy duration AND
Criteria 5: Clinical documentation of patient’s prior treatment including drug name and date(s) of therapy AND
Criteria 6: Pretreatment detectable HCV RNA viral load value, measured within 1 year of treatment start date, are provided at time of request AND
Criteria 7: Provider attests to submits SVR12 results to the Department via fax at 651-431-7424 or upon request AND
Criteria 8: Patient is 18 years of age or older with a diagnosis of hepatitis C, genotype 1.
Treatment-Naïve Patients
Preferred | Nonpreferred |
Mavyret | Epclusa
Sovaldi |
Treatment-Experienced Patients
Preferred | Nonpreferred |
Mavyret
Vosevi |
None |
Criteria 1: Regimen is prescribed by (or had a documented consult with) a gastroenterologist, hepatologist, infectious disease specialist, or a practitioner specializing in the treatment of hepatitis. Notes of consultation with specialist must be attached to authorization request AND
Criteria 2: Both the treating clinician and the patient are confident that the patient can effectively start and successfully adhere to treatment. The treating clinician must attest that the patient has been evaluated for “readiness” for treatment, including identification of potential impediments to effective treatment (e.g., difficulties with compliance, missing appointments, adequate social support, and adequate control of mental health conditions, alcohol use disorder, and IV drug use). Potential impediments to successful treatment must be addressed in treatment notes prior to initiating treatment and submitted with authorization request. Specifically:
Criteria 3: The treating clinician must provide documentation to attest the patient is screened for evidence of current or prior hepatitis B virus (HBV) infection before starting treatment with direct acting antivirals. The treating clinician must also have a monitoring plan in place for HBV flare-ups or reactivation during treatment and post-treatment follow up AND
Where indicated, the treating clinician must provide documentation that the patient has been counseled on the HBV reactivation adverse events management plan, including the risks of HBV reactivation, including serious liver injury and death AND
Criteria 4: Clinical documentation of patient’s liver cirrhosis status (e.g., no cirrhosis, compensated cirrhosis, etc.) that corresponds to the requested therapy duration AND
Criteria 5: Pretreatment detectable HCV RNA viral load value, measured within 1 year of treatment start date, are provided at time of request AND
Criteria 6: Provider attests to submits SVR12 results to the Department via fax at 651-431-7424 or upon request AND
Criteria 7: Patient is 18 years of age or older with a diagnosis of hepatitis C, genotype 2.
For patients under the age of 18 requesting Sovaldi:
Patient has met Criteria 1 through 6 of the Preferred Drug Criteria AND
Patient has a diagnosis of hepatitis C, genotype 2 AND
Patient will use Sovaldi in combination with ribavirin AND
Patient meets either of the following:
For patients over the age of 18:
Patient has met Criteria 1 through 7 of the Preferred Drug Criteria AND
Patient meets the drug specific criteria in Table 3, Tier Approach to Nonpreferred Drugs for Treatment-Naïve, Genotype 2 AND
Patient has HCV infection with at least ONE of the four conditions listed below:
Tier | Nonpreferred Drug | PA Criteria |
1 | Epclusa | Must meet all PA criteria for nonpreferred drug above. Patient also must have creatinine clearance (CrCL) > 30 mL/min OR not currently on hemodialysis. |
2 | Sovaldi | Must meet all PA criteria for nonpreferred drug above and have a contraindication to Epclusa. Sovaldi must be used in combination with ribavirin. Patient also must have creatinine clearance (CrCL) > 30 mL/min OR not currently on hemodialysis. |
Criteria 1: Regimen is prescribed by (or had a documented consult with) a gastroenterologist, hepatologist, infectious disease specialist, or a practitioner specializing in the treatment of hepatitis. Notes of consultation with specialist must be attached to authorization request AND
Criteria 2: Both the treating clinician and the patient are confident that the patient can effectively start and successfully adhere to treatment. The treating clinician must attest that the patient has been evaluated for “readiness” for treatment, including identification of potential impediments to effective treatment (e.g., difficulties with compliance, missing appointments, adequate social support, and adequate control of mental health conditions, alcohol use disorder, and IV drug use). Potential impediments to successful treatment must be addressed in treatment notes prior to initiating treatment and submitted with authorization request. Specifically:
Criteria 3: The treating clinician must provide documentation to attest that the patient is screened for evidence of current or prior hepatitis B virus (HBV) infection before starting treatment with direct acting antivirals AND the provider has a monitoring plan for HBV flare-ups or reactivation during treatment and post-treatment follow-up AND
Criteria 4: Clinical documentation of patient’s liver cirrhosis status (e.g., no cirrhosis, compensated cirrhosis, etc.) that corresponds to the requested therapy duration AND
Criteria 5: Clinical documentation of patient’s prior treatment including drug name and date(s) of therapy AND
Criteria 6: Pretreatment detectable HCV RNA viral load value, measured within 1 year of treatment start date, are provided at time of request AND
Criteria 7: Provider attests to submits SVR12 results to the Department via fax at 651-431-7424 or upon request AND
Criteria 8: Patient is 18 years of age or older with a diagnosis of hepatitis C, genotype 2.
Treatment-Naïve Patients
Preferred | Nonpreferred |
Mavyret | Epclusa
Sovaldi Daklinza |
Treatment-Experienced Patients
Preferred | Nonpreferred |
Mavyret
Vosevi |
None |
Criteria 1: Regimen is prescribed by (or had a documented consult with) a gastroenterologist, hepatologist, infectious disease specialist, or a practitioner specializing in the treatment of hepatitis. Notes of consultation with specialist must be attached to authorization request AND
Criteria 2: Both the treating clinician and the patient are confident that the patient can effectively start and successfully adhere to treatment. The treating clinician must attest that the patient has been evaluated for “readiness” for treatment, including identification of potential impediments to effective treatment (e.g., difficulties with compliance, missing appointments, adequate social support, and adequate control of mental health conditions, alcohol use disorder, and IV drug use). Potential impediments to successful treatment must be addressed in treatment notes prior to initiating treatment and submitted with authorization request. Specifically:
Criteria 3: The treating clinician must provide documentation to attest the patient is screened for evidence of current or prior hepatitis B virus (HBV) infection before starting treatment with direct acting antivirals. The treating clinician must also have a monitoring plan in place for HBV flare-ups or reactivation during treatment and post-treatment follow up AND
Criteria 4: Clinical documentation of patient’s liver cirrhosis status (e.g., no cirrhosis, compensated cirrhosis, etc.) that corresponds to the requested therapy duration AND
Criteria 5: Pretreatment detectable HCV RNA viral load value, measured within 1 year of treatment start date, are provided at time of request AND
Criteria 6: Provider attests to submits SVR12 results to the Department via fax at 651-431-7424 or upon request AND
Criteria 7: Patient is 18 years of age or older with a diagnosis of hepatitis C, genotype 3.
For patients under the age of 18 requesting Sovaldi:
Patient has met Criteria 1 through 6 of the Preferred Drug Criteria AND
Patient has a diagnosis of hepatitis C, genotype 3 AND
Patient will use Sovaldi in combination with ribavirin AND
Patient meets either of the following:
For patients over the age of 18:
Patient has met Criteria 1 through 7 of the Preferred Drug Criteria AND
Patient meets the drug specific criteria in Table 4, Tier Approach to Nonpreferred Drugs for Treatment-Naïve, Genotype 3 AND
Patient has HCV infection with at least ONE of the four conditions listed below:
Tier | Nonpreferred Drug | PA Criteria |
1 | Epclusa | Must meet all PA criteria for nonpreferred drug above. Patient also must have creatinine clearance (CrCL) > 30 mL/min OR not currently on hemodialysis. |
2 | Sovaldi | Must meet all PA criteria for nonpreferred drug above and have a contraindication to Epclusa and Sovaldi must be used in combination with ribavirin. Patient also must have creatinine clearance (CrCL) > 30 mL/min OR not currently on hemodialysis. |
3 | Daklinza | Must meet all PA criteria for nonpreferred drug above and have a contraindication to Epclusa and Daklinza must be used in combination with Sovaldi. Patient also must have creatinine clearance (CrCL) > 30 mL/min OR not currently on hemodialysis. |
Criteria 1: Regimen is prescribed by (or had a documented consult with) a gastroenterologist, hepatologist, infectious disease specialist, or a practitioner specializing in the treatment of hepatitis. Notes of consultation with specialist must be attached to authorization request AND
Criteria 2: Both the treating clinician and the patient are confident that the patient can effectively start and successfully adhere to treatment. The treating clinician must attest that the patient has been evaluated for “readiness” for treatment, including identification of potential impediments to effective treatment (e.g., difficulties with compliance, missing appointments, adequate social support, and adequate control of mental health conditions, alcohol use disorder, and IV drug use). Potential impediments to successful treatment must be addressed in treatment notes prior to initiating treatment and submitted with authorization request. Specifically:
Criteria 3: The treating clinician must provide documentation to attest that the patient is screened for evidence of current or prior hepatitis B virus (HBV) infection before starting treatment with direct acting antivirals AND the provider has a monitoring plan for HBV flare-ups or reactivation during treatment and post-treatment follow-up AND
Criteria 4: Clinical documentation of patient’s liver cirrhosis status (e.g., no cirrhosis, compensated cirrhosis, etc.) that corresponds to the requested therapy duration AND
Criteria 5: Clinical documentation of patient’s prior treatment including drug name and date(s) of therapy AND
Criteria 6: Pretreatment detectable HCV RNA viral load value, measured within 1 year of treatment start date, are provided at time of request AND
Criteria 7: Provider attests to submits SVR12 results to the Department via fax at 651-431-7424 or upon request AND
Criteria 8: Patient is 18 years of age or older with a diagnosis of hepatitis C, genotype 3.
Treatment-Naïve Patients
Preferred | Nonpreferred |
Mavyret | Technivie
Zepatier Harvoni Epclusa Sovaldi |
Treatment-Experienced Patients
Preferred | Nonpreferred |
Mavyret
Vosevi |
None |
Criteria 1: Regimen is prescribed by (or had a documented consult with) a gastroenterologist, hepatologist, infectious disease specialist, or a practitioner specializing in the treatment of hepatitis. Notes of consultation with specialist must be attached to authorization request AND
Criteria 2: Both the treating clinician and the patient are confident that the patient can effectively start and successfully adhere to treatment. The treating clinician must attest that the patient has been evaluated for “readiness” for treatment, including identification of potential impediments to effective treatment (e.g., difficulties with compliance, missing appointments, adequate social support, and adequate control of mental health conditions, alcohol use disorder, and IV drug use). Potential impediments to successful treatment must be addressed in treatment notes prior to initiating treatment and submitted with authorization request. Specifically:
Criteria 3: The treating clinician must provide documentation to attest the patient is screened for evidence of current or prior hepatitis B virus (HBV) infection before starting treatment with direct acting antivirals. The treating clinician must also have a monitoring plan in place for HBV flare-ups or reactivation during treatment and post-treatment follow up AND
Criteria 4: Clinical documentation of patient’s liver cirrhosis status (e.g., no cirrhosis, compensated cirrhosis, etc.) that corresponds to the requested therapy duration AND
Criteria 5: Pretreatment detectable HCV RNA viral load value, measured within 1 year of treatment start date, are provided at time of request AND
Criteria 6: Provider attests to submits SVR12 results to the Department via fax at 651-431-7424 or upon request AND
Criteria 7: Patient is 18 years of age or older with a diagnosis of hepatitis C, genotype 4.
For patients under the age of 18 requesting Harvoni:
Patient has met Criteria 1 through 6 of the Preferred Drug Criteria AND
Patient has a diagnosis of hepatitis C, genotype 4 AND
Patient meets either of the following:
For patients over the age of 18:
Patient has met Criteria 1 through 7 of the Preferred Drug Criteria AND
Patient meets the drug specific criteria in Table 5, Tier Approach to Nonpreferred Drugs for Treatment-Naïve, Genotype 4 AND
Patient has HCV infection with at least ONE of the four conditions listed below:
Tier | Nonpreferred Drug | PA Criteria |
1 | Technivie | Must meet all PA criteria for nonpreferred drug above. Patient also must not be on dialysis. |
2 | Zepatier | Must meet all PA criteria for nonpreferred drug above and has renal impairment. Patient must also have a contraindication to Technivie. |
3 | Harvoni | Must meet all PA criteria for nonpreferred drug above and have a contraindication to Technivie and Zepatier. Patient also must have creatinine clearance (CrCL) > 30 mL/min OR not currently on hemodialysis. |
4 | Epclusa | Must meet all PA criteria for nonpreferred drug above and have a contraindication to Technivie and Zepatier and supply clinical rationale as to why Harvoni cannot be used. Patient also must have creatinine clearance (CrCL) > 30 mL/min OR not currently on hemodialysis. |
5 | Sovaldi | Must meet all PA criteria for nonpreferred drug above and have a contraindication to Technivie and Zepatier and supply clinical rationale as to why Harvoni and Epclusa cannot be used. Patient also must have creatinine clearance (CrCL) > 30 mL/min OR not currently on hemodialysis and
Must be used in combination with Peg-IFN-alfa and ribavirin. |
Criteria 1: Regimen is prescribed by (or had a documented consult with) a gastroenterologist, hepatologist, infectious disease specialist, or a practitioner specializing in the treatment of hepatitis. Notes of consultation with specialist must be attached to authorization request AND
Criteria 2: Both the treating clinician and the patient are confident that the patient can effectively start and successfully adhere to treatment. The treating clinician must attest that the patient has been evaluated for “readiness” for treatment, including identification of potential impediments to effective treatment (e.g., difficulties with compliance, missing appointments, adequate social support, and adequate control of mental health conditions, alcohol use disorder, and IV drug use). Potential impediments to successful treatment must be addressed in treatment notes prior to initiating treatment and submitted with authorization request. Specifically:
Criteria 3: The treating clinician must provide documentation to attest that the patient is screened for evidence of current or prior hepatitis B virus (HBV) infection before starting treatment with direct acting antivirals AND the provider has a monitoring plan for HBV flare-ups or reactivation during treatment and post-treatment follow-up AND
Criteria 4: Clinical documentation of patient’s liver cirrhosis status (e.g., no cirrhosis, compensated cirrhosis, etc.) that corresponds to the requested therapy duration AND
Criteria 5: Clinical documentation of patient’s prior treatment including drug name and date(s) of therapy AND
Criteria 6: Pretreatment detectable HCV RNA viral load value, measured within 1 year of treatment start date, are provided at time of request AND
Criteria 7: Provider attests to submits SVR12 results to the Department via fax at 651-431-7424 or upon request AND
Criteria 8: Patient is 18 years of age or older with a diagnosis of hepatitis C, genotype 4.
Treatment-Naïve Patients
Preferred | Nonpreferred |
Mavyret | Harvoni
Epclusa |
Treatment-Experienced Patients
Preferred | Nonpreferred |
Mavyret
Vosevi |
None |
Criteria 1: Regimen is prescribed by (or had a documented consult with) a gastroenterologist, hepatologist, infectious disease specialist, or a practitioner specializing in the treatment of hepatitis. Notes of consultation with specialist must be attached to authorization request AND
Criteria 2: Both the treating clinician and the patient are confident that the patient can effectively start and successfully adhere to treatment. The treating clinician must attest that the patient has been evaluated for “readiness” for treatment, including identification of potential impediments to effective treatment (e.g., difficulties with compliance, missing appointments, adequate social support, and adequate control of mental health conditions, alcohol use disorder, and IV drug use). Potential impediments to successful treatment must be addressed in treatment notes prior to initiating treatment and submitted with authorization request. Specifically:
Criteria 3: The treating clinician must provide documentation to attest the patient is screened for evidence of current or prior hepatitis B virus (HBV) infection before starting treatment with direct acting antivirals. The treating clinician must also have a monitoring plan in place for HBV flare-ups or reactivation during treatment and post-treatment follow up AND
Criteria 4: Clinical documentation of patient’s liver cirrhosis status (e.g., no cirrhosis, compensated cirrhosis, etc.) that corresponds to the requested therapy duration AND
Criteria 5: Pretreatment detectable HCV RNA viral load value, measured within 1 year of treatment start date, are provided at time of request AND
Criteria 6: Provider attests to submits SVR12 results to the Department via fax at 651-431-7424 or upon request AND
Criteria 7: Patient is 18 years of age or older with a diagnosis of hepatitis C, genotype 5 or 6.
For patients under the age of 18 requesting Harvoni:
Patient has met Criteria 1 through 6 of the Preferred Drug Criteria AND
Patient has a diagnosis of hepatitis C, genotype 5 or 6 AND
Patient meets either of the following:
For patients over the age of 18:
Patient has met Criteria 1 through 7 of the Preferred Drug Criteria AND
Patient meets the drug specific criteria in Table 6, Tier Approach to Nonpreferred Drugs for Treatment-Naïve, Genotype 5 or 6 AND
Patient has HCV infection with at least ONE of the four conditions listed below:
Tier | Nonpreferred Drug | PA Criteria |
1 | Harvoni | Must meet all PA criteria for nonpreferred drug above. Patient also must have creatinine clearance (CrCL) > 30 mL/min OR not currently on hemodialysis. |
2 | Epclusa | Must meet all PA criteria for nonpreferred drug above and have a contraindication to Harvoni. Patient also must have creatinine clearance (CrCL) > 30 mL/min OR not currently on hemodialysis |
Criteria 1: Regimen is prescribed by (or had a documented consult with) a gastroenterologist, hepatologist, infectious disease specialist, or a practitioner specializing in the treatment of hepatitis. Notes of consultation with specialist must be attached to authorization request AND
Criteria 2: Both the treating clinician and the patient are confident that the patient can effectively start and successfully adhere to treatment. The treating clinician must attest that the patient has been evaluated for “readiness” for treatment, including identification of potential impediments to effective treatment (e.g., difficulties with compliance, missing appointments, adequate social support, and adequate control of mental health conditions, alcohol use disorder, and IV drug use). Potential impediments to successful treatment must be addressed in treatment notes prior to initiating treatment and submitted with authorization request. Specifically:
Criteria 3: The treating clinician must provide documentation to attest that the patient is screened for evidence of current or prior hepatitis B virus (HBV) infection before starting treatment with direct acting antivirals AND the provider has a monitoring plan for HBV flare-ups or reactivation during treatment and post-treatment follow-up AND
Criteria 4: Clinical documentation of patient’s liver cirrhosis status (e.g., no cirrhosis, compensated cirrhosis, etc.) that corresponds to the requested therapy duration AND
Criteria 5: Clinical documentation of patient’s prior treatment including drug name and date(s) of therapy AND
Criteria 6: Pretreatment detectable HCV RNA viral load value, measured within 1 year of treatment start date, are provided at time of request AND
Criteria 7: Provider attests to submits SVR12 results to the Department via fax at 651-431-7424 or upon request AND
Criteria 8: Patient is 18 years of age or older with a diagnosis of hepatitis C, genotype 5 or 6.
MHCP Provider Call Center 651-431-2700 or 800-366-5411